/
/
/

Glenmark Pharmaceuticals Profit & Loss

Consolidated
Standalone
Quarterly
Yearly
%
Name
Net Revenue
Other Income
Total Revenue
Total Expenditure
Operating Profit
Interest Expense
PBT
Net Profit
Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023Mar 2023Dec 2022Sep 2022Jun 2022Mar 2022Dec 2021Sep 2021Jun 2021Mar 2021Dec 2020Sep 2020Jun 2020Mar 2020Dec 2019Sep 2019Jun 2019Mar 2019Dec 2018Sep 2018Jun 2018Mar 2018Dec 2017Sep 2017Jun 2017Mar 2017Dec 2016Sep 2016Jun 2016Mar 2016Dec 2015Sep 2015Jun 2015Mar 2015Dec 2014Sep 2014Jun 2014Mar 2014Dec 2013Sep 2013Jun 2013Mar 2013Dec 2012Sep 2012
₹4018 Cr₹3771 Cr₹3901 Cr₹6047 Cr₹3264 Cr₹3256 Cr₹3388 Cr₹3434 Cr₹3244 Cr₹3063 Cr₹2507 Cr₹3207 Cr₹3036 Cr₹3001 Cr₹3100 Cr₹3375 Cr₹2777 Cr₹3019 Cr₹3173 Cr₹3147 Cr₹2965 Cr₹2860 Cr₹2787 Cr₹2952 Cr₹2345 Cr₹2767 Cr₹2736 Cr₹2815 Cr₹2323 Cr₹2563 Cr₹2555 Cr₹2581 Cr₹2166 Cr₹2280 Cr₹2204 Cr₹2257 Cr₹2363 Cr₹2457 Cr₹2535 Cr₹2224 Cr₹1969 Cr₹2307 Cr₹1778 Cr₹1909 Cr₹1648 Cr₹1776 Cr₹1701 Cr₹1681 Cr₹1487 Cr₹1704 Cr₹1602 Cr₹1463 Cr₹1238 Cr₹1336 Cr₹1382 Cr₹1256 Cr
₹66 Cr₹189 Cr₹44 Cr₹201 Cr₹26 Cr₹12 Cr₹31 Cr₹39 Cr₹31 Cr₹773 Cr₹45 Cr₹2 Cr₹20 Cr-₹42 Cr₹71 Cr₹97 Cr₹183 Cr₹107 Cr₹14 Cr-₹13 Cr₹59 Cr₹8 Cr₹15 Cr-₹32 Cr₹59 Cr₹44 Cr₹33 Cr₹81 Cr₹2 Cr₹39 Cr-₹109 Cr₹140 Cr₹138 Cr₹70 Cr-₹23 Cr₹30 Cr₹15 Cr-₹51 Cr₹15 Cr-₹2 Cr₹76 Cr₹12 Cr₹2 Cr₹80 L₹5 Cr₹33 L₹2 Cr₹97 L₹3 Cr-₹12 Cr₹5 Cr₹13 Cr₹3 Cr-₹5 Cr₹5 Cr₹7 Cr
₹4084 Cr₹3960 Cr₹3945 Cr₹6248 Cr₹3291 Cr₹3268 Cr₹3419 Cr₹3473 Cr₹3276 Cr₹3836 Cr₹2552 Cr₹3209 Cr₹3056 Cr₹2958 Cr₹3171 Cr₹3473 Cr₹2960 Cr₹3126 Cr₹3187 Cr₹3134 Cr₹3024 Cr₹2868 Cr₹2802 Cr₹2921 Cr₹2403 Cr₹2812 Cr₹2769 Cr₹2896 Cr₹2325 Cr₹2603 Cr₹2446 Cr₹2721 Cr₹2304 Cr₹2349 Cr₹2181 Cr₹2286 Cr₹2378 Cr₹2406 Cr₹2550 Cr₹2222 Cr₹2045 Cr₹2318 Cr₹1780 Cr₹1910 Cr₹1653 Cr₹1776 Cr₹1703 Cr₹1682 Cr₹1490 Cr₹1691 Cr₹1607 Cr₹1477 Cr₹1242 Cr₹1331 Cr₹1387 Cr₹1262 Cr
₹3387 Cr₹3156 Cr₹3185 Cr₹3829 Cr₹2814 Cr₹2820 Cr₹2910 Cr₹2952 Cr₹2774 Cr₹2710 Cr₹2862 Cr₹2887 Cr₹2741 Cr₹2738 Cr₹2778 Cr₹2909 Cr₹2492 Cr₹2687 Cr₹2599 Cr₹2680 Cr₹2504 Cr₹2448 Cr₹2372 Cr₹2504 Cr₹1980 Cr₹2428 Cr₹2401 Cr₹2459 Cr₹2072 Cr₹2280 Cr₹2203 Cr₹2224 Cr₹1898 Cr₹2027 Cr₹1956 Cr₹1943 Cr₹1863 Cr₹2082 Cr₹1833 Cr₹1844 Cr₹1655 Cr₹2062 Cr₹1459 Cr₹1565 Cr₹1354 Cr₹1559 Cr₹1501 Cr₹1410 Cr₹1210 Cr₹1382 Cr₹1298 Cr₹1208 Cr₹1025 Cr₹1108 Cr₹1097 Cr₹1016 Cr
₹871 Cr₹952 Cr₹914 Cr₹2560 Cr₹607 Cr₹573 Cr₹631 Cr₹641 Cr₹620 Cr₹1278 Cr-₹163 Cr₹464 Cr₹457 Cr₹355 Cr₹545 Cr₹719 Cr₹615 Cr₹571 Cr₹707 Cr₹577 Cr₹632 Cr₹532 Cr₹545 Cr₹521 Cr₹537 Cr₹510 Cr₹473 Cr₹531 Cr₹344 Cr₹403 Cr₹326 Cr₹580 Cr₹485 Cr₹396 Cr₹300 Cr₹418 Cr₹593 Cr₹393 Cr₹780 Cr₹447 Cr₹455 Cr₹315 Cr₹373 Cr₹405 Cr₹365 Cr₹282 Cr₹268 Cr₹336 Cr₹346 Cr₹370 Cr₹370 Cr₹329 Cr₹251 Cr₹255 Cr₹325 Cr₹278 Cr
₹54 Cr₹43 Cr₹41 Cr₹66 Cr₹58 Cr₹67 Cr₹52 Cr₹48 Cr₹40 Cr₹149 Cr₹134 Cr₹121 Cr₹112 Cr₹109 Cr₹97 Cr₹83 Cr₹60 Cr₹87 Cr₹67 Cr₹69 Cr₹76 Cr₹83 Cr₹95 Cr₹81 Cr₹94 Cr₹98 Cr₹96 Cr₹90 Cr₹93 Cr₹82 Cr₹89 Cr₹85 Cr₹79 Cr₹74 Cr₹70 Cr₹70 Cr₹71 Cr₹70 Cr₹62 Cr₹63 Cr₹43 Cr₹48 Cr₹47 Cr₹43 Cr₹42 Cr₹40 Cr₹51 Cr₹51 Cr₹48 Cr₹46 Cr₹47 Cr₹48 Cr₹46 Cr₹44 Cr₹40 Cr₹38 Cr
₹643 Cr₹388 Cr₹534 Cr₹967 Cr₹96 Cr₹8 Cr₹456 Cr₹473 Cr₹462 Cr₹531 Cr-₹521 Cr-₹124 Cr₹151 Cr-₹688 Cr₹330 Cr₹480 Cr₹408 Cr₹270 Cr₹343 Cr₹385 Cr₹444 Cr₹338 Cr₹348 Cr₹339 Cr₹358 Cr₹318 Cr₹271 Cr₹347 Cr₹160 Cr₹240 Cr₹154 Cr₹580 Cr₹327 Cr₹248 Cr₹154 Cr₹273 Cr₹444 Cr₹173 Cr₹655 Cr₹315 Cr₹348 Cr₹209 Cr₹274 Cr₹303 Cr₹257 Cr-₹9 Cr₹151 Cr₹220 Cr₹233 Cr₹45 Cr₹262 Cr₹220 Cr₹170 Cr₹180 Cr₹250 Cr₹207 Cr
₹483 Cr₹301 Cr₹403 Cr₹610 Cr₹47 Cr₹4 Cr₹348 Cr₹354 Cr₹340 Cr-₹1214 Cr-₹331 Cr-₹62 Cr₹173 Cr-₹403 Cr₹291 Cr₹279 Cr₹211 Cr₹173 Cr₹240 Cr₹275 Cr₹307 Cr₹234 Cr₹248 Cr₹234 Cr₹254 Cr₹220 Cr₹191 Cr₹256 Cr₹109 Cr₹162 Cr₹116 Cr₹414 Cr₹233 Cr₹152 Cr₹105 Cr₹214 Cr₹333 Cr₹184 Cr₹477 Cr₹224 Cr₹227 Cr₹149 Cr₹196 Cr₹216 Cr₹183 Cr₹11 Cr₹115 Cr₹165 Cr₹185 Cr₹43 Cr₹214 Cr₹157 Cr₹131 Cr₹175 Cr₹213 Cr₹160 Cr

Share Price Live Stats

Open (₹)2,454.50
Volume (₹)3.16 L
High (₹)2,456.70
Upper Circuit2,704.90
Low (₹)2,422.70
Lower Circuit2,213.10
Prev Close2,459.00
52W High (₹)2,537.60
Price2,434.50
52W Low (₹)1,792.60

Share Market Cap & Key Ratios Overview

M.Cap (₹)69393.40 Cr
Div. Yield (%)0.10
PE Ratio38.60
Debt to Equity0.00
Price to Book5.75
Book Value371.30
EPS (TTM)63.70
Face Value1.00
ROE (%)14.10

Stock Analysis (SWOT)

StrengthsWeaknessesOpportunitiesThreats
1. Premium insight available after login
2. Sign in to view full SWOT analysis
3. Unlock strengths, weaknesses, opportunities & threats
Sign in to view
Open a free Demat account in minutes to start investing and screening .

QVT

Quality
0/100-
Valuation
0/100-
Technical
0/100-
Sign in to view
Open a free Demat account in minutes to start investing and screening .

Peer Stocks

1 week
1 month
1 year
Name
SUNPHARMANSE
DIVISLABNSE
TORNTPHARMNSE
ZYDUSLIFENSE
CIPLANSE
LAURUSLABSNSE
LUPINNSE
MANKINDNSE
DRREDDYNSE
AUROPHARMANSE
GLENMARKNSE
LTP
1W Low
1W High
Market cap (₹)
1900.7-19.3 (-1.01%)
1896.80
1984.80
4,56,833Cr
9157.5-81.5 (-0.88%)
9087
9467
2,45,426Cr
4843.5-206.5 (-4.09%)
4823
5066
1,87,320Cr
1129.5-61.5 (-5.16%)
1125.10
1187
1,13,217Cr
1381.6-41.9 (-2.94%)
1376
1426.10
1,12,212Cr
1845.5-93 (-4.80%)
1811.70
1949
1,01,155Cr
2113.9-57.6 (-2.65%)
2107.20
2192
97,626Cr
2332.7-50.2 (-2.11%)
2327.30
2419.20
96,859Cr
1158.6-19.4 (-1.65%)
1154.40
1179.90
96,406Cr
1651.2+5.9 (0.36%)
1622.60
1717
93,614Cr
2434.5-80.5 (-3.20%)
2420
2532.40
69,393Cr

Key Highlights of Glenmark Pharmaceuticals Ltd’s P&L

In 2026-03-31, Glenmark Pharmaceuticals Ltd reported total revenue of ₹17443.12Cr, compared with ₹13435.42Cr in 2025-03-31, reflecting Glenmark Pharmaceuticals Ltd turnover.

Depreciation was ₹573.48Cr and finance costs were ₹208.72Cr in 2026-03-31

Profit Before Tax (PBT) has been ₹1984.75Cr in 2026-03-31 as compared to ₹1399.21Cr in 2025-03-31.

Net Profit (PAT) was ₹1361.85Cr in 2026-03-31 compared with ₹1047.1Cr in 2025-03-31.

Earnings per share (EPS) were ₹48.26 in 2026-03-31, compared with ₹37.11 in 2025-03-31.